Imagine spending years living on the edge of your family's story. You know something is wrong with your brother or sister.
Children with moderate to severe atopic dermatitis had improved skin barrier function with 16-week dupilumab treatment in both lesional and nonlesional skin, according to data published in Annals of ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
The most common concerns include which foods might cause or trigger atopic dermatitis, when to introduce solid foods, and ...
Use of digital health technology for disease monitoring continues to expand, but data on real-world applications in people ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results